Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement
- PMID: 30742733
- PMCID: PMC6617751
- DOI: 10.1111/bju.14707
Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement
Abstract
Objectives: To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts.
Subjects and methods: A consensus statement was drafted on the basis of three sources of data: systematic literature search of national and international guidelines; data arising from a Freedom of Information Act request to UK urology departments regarding their current practice of AS; and survey and interview responses from men with localized prostate cancer regarding their experiences and views of AS. The Prostate Cancer UK Expert Reference Group (ERG) on AS was then convened to discuss and refine the statement.
Results: Guidelines and protocols for AS varied significantly in terms of risk stratification, criteria for offering AS, and protocols for AS between and within countries. Patients and healthcare professionals identified clinical, emotional and process needs for AS to be effective. Men with prostate cancer wanted more information and psychological support at the time of discussing AS with the treating team and in the first 2 years of AS, and a named healthcare professional to discuss any questions or concerns they had. The ERG agreed 30 consensus statements regarding best practice for AS. Statements were grouped under headings: 'Inclusion/Exclusion Criteria'; 'AS follow-up protocol' and 'When to stop AS'.
Conclusion: Significant variation currently exists in the practice of AS in the UK and internationally. Men have clear views on the level of involvement in treatment decisions and support from their treating professionals when receiving AS. The Prostate Cancer UK AS ERG has developed a set of consensus statements for best practice in AS. Evidence for best practice in AS, and the use of multiparametric magnetic resonance imaging in AS, is still evolving, and further studies are needed to determine how to optimize AS outcomes.
Keywords: #PCSM; #ProstateCancer; #uroonc; active surveillance; clinical consensus; guidelines.
© 2019 The Authors BJU International Published by John Wiley & Sons Ltd on behalf of BJU International.
Conflict of interest statement
None declared.
References
-
- Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, 2013. Available at: http://globocan.iarc.fr Accessed May 2018
-
- Dahabreh IJ, Chung M, Balk EM, Yu WW, Mathew P. Active Surveillance in men with localized prostate cancer. Ann Intern Med 2012; 156: 582–90 - PubMed
-
- Hamdy FC, Donovan JL, Lane JA, et al. 10‐year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–24 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
